Investigating how VHL tumor suppressor affects kidney cancer
Official title: New Von Hippel Lindau (VHL) tumor suppressor signaling in renal cancer
Funded at Ut Southwestern Medical Center · NIH-10997272 · Data updated 2026-11-12
This study is looking at a type of kidney cancer called clear cell renal cell carcinoma and how a specific gene, VHL, affects cancer cells, with the hope of finding new ways to treat patients who have this challenging condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | August 7, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $546,349 |
| NIH project number | 1R01CA294636-01 |
| Project ID | NIH-10997272 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma, particularly those with VHL deficiency.
✕Less likely to help
Patients with other types of kidney cancer or those whose cancer is not associated with VHL may not benefit from this research.
What this research studies
This research focuses on clear cell renal cell carcinoma (ccRCC), a type of kidney cancer that is often resistant to treatment. It explores the role of the von Hippel-Lindau (VHL) tumor suppressor and its interaction with a specific RNA modification process called m6A, which may influence cancer cell behavior. By analyzing gene expression in kidney cells with and without VHL, the research aims to uncover new therapeutic targets that could improve treatment outcomes for patients with VHL-deficient ccRCC.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced kidney cancer that are currently difficult to treat.
How similar studies have gone: Previous research has shown promising results in targeting m6A modifications in cancer, suggesting that this approach may yield valuable insights and potential breakthroughs.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Zhang, Qing — Ut Southwestern Medical Center
- Study coordinator: Zhang, Qing
Related research
Other NIH-funded projects on the same topics.
-
Profilin as a Target to Normalize Tumor Vessels in Kidney Cancer
A new approach aims to curb blood vessel growth in a common kidney cancer by targeting a protein called Profilin 1 to improve how blood vessels form in tumors.
-
Overcoming obesity-related resistance to immunotherapy in kidney cancer
A study aims to understand why obesity affects how well immunotherapy works for people with advanced kidney cancer and how to improve treatments for those patients.
-
Copper-driven metabolism in clear cell kidney cancer relapse
This grant studies how copper metabolism affects the growth and relapse of clear cell renal cell carcinoma to identify new ways to help patients after surgery.
-
New VHL tumor-suppressor signaling in kidney cancer
This project looks at why a common kidney cancer (ccRCC) resists treatment and how changes in a gene called VHL and a chemical tag on RNA might open new ways to fight it.
-
Targeting epigenetic drivers in clear cell kidney cancer
A doctor-scientist at Johns Hopkins is exploring how epigenetic changes shape kidney cancer and whether new therapies can target these changes.
-
Targeting profilin to normalize blood vessels in kidney cancer
This work tests whether blocking a protein called profilin can normalize tumor blood vessels and help people with clear cell kidney cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.